Abstract. The upregulation of long non-coding RNA (lncRNA) human ovarian cancer-specific transcript 2 (HOST2) has been identified in breast cancer. The present study aimed to investigate whether lncRNA HOST2 regulated the proliferation of triple negative breast cancer (TNBC) cells, and the underlying molecular mechanism. In total, 30 patients with primary TNBC, who were treated at Wuhai People's Hospital (Wuhai, China), were recruited for the present study. Reverse transcription-quantitative polymerase chain reaction analysis was used for the examination of gene expression levels. A Cell Counting kit-8 (CCK-8) assay was used for the detection of cell proliferation. Phases of the cell cycle were evaluated by flow cytometry. Western blot analysis was performed to detect protein expression levels. A dual luciferase activity assay was performed to examine the interaction between microRNA (miRNA) and the 3' untranslated region (UTR) of target mRNA. The results revealed increased expression levels of HOST2 in tumor tissues from patients with TNBC. A positive correlation was identified between the expression of HOST2 and cyclin-dependent kinase 6 (CDK6) in tumor tissues. The silencing of HOST2 induced cell proliferation inhibition and cell cycle redistribution in MDA-MB-231 and MDA-MB-468 TNBC cells. In these two cell lines, HOST2 silencing caused a decrease in the phosphorylation of RB1 and CDK6, which was observed at the mRNA and protein levels. However, the silencing of CDK6 did not alter the expression of HOST2. It was hypothesized and confirmed that let-7b, a previously reported target miRNA of HOST2, was able to directly bind to the 3'UTR of CDK6 and repress its expression. The expression of let-7b was negatively correlated with the expression of HOST2 and CDK6 in tumor tissues. Overall, the data suggested that lncRNA HOST2 acts as an oncogene in TNBC via the upregulation of CDK6.

Introduction

Breast cancer is among the most common types of cancer in female patients, with a high global mortality rate (1). Over 1,000,000 women are diagnosed each year, and ≥410,000 diagnosed patients succumb to mortality, accounting for ~14.0% of cases of cancer-associated mortality in women (2). In recent years, the incidence of breast cancer has increased by 3% each year in China, seriously threatening the health of women and causing a burden on society (3). According to gene expression profiling, breast cancer is categorized into four major subtypes: Luminal A, luminal B, human epidermal growth factor receptor 2 positive (Her2+) and basal-like (4). Different subgroups are associated with different clinical outcomes (1). However, triple negative-breast cancer (TNBC), which is characterized by the lack of estrogen receptor, progesterone receptor, and expression of Her-2, is not effectively treated by endocrine therapy or Her-2-targeted therapy (5). TNBC has been a popular focus of investigation in clinical and scientific fields over the last decade (6). Since 2014, the correlation between the progression of TNBC and epigenetics has been investigated thoroughly (7). The identification of effective therapies for TNBC is urgent.

Long non-coding RNAs (lncRNAs), which are RNA molecules >200 nt in length, are important in a large number of cellular processes, including alterations of the cell- or tissue-specific expression profile, and the promotion of cell proliferation, metastasis and invasion (8). lncRNAs have been reported to be of significance in the diagnosis and treatment of multiple types of disease, specifically the tumorigenesis and progression of various types of cancer, including osteosarcoma and TNBC (9,10). The functions of lncRNAs include modulation of gene methylation, activation of transcription, regulation of translation and other processes in conjunction with mRNAs and microRNAs (miRNAs) (11). Human ovarian
cancer-specific transcript 2 (HOST2) is an lncRNA of 2.9 kb, with no identified open reading frame (12). The lncRNA HOST2 is expressed at high levels in epithelial ovarian cancer, and the inhibition of HOST2 has been demonstrated to reduce the proliferation, migration and invasion of ovarian cancer cells (13).

Accordingly, the present study aimed to investigate the effects of lncRNA HOST2 on TNBC cell proliferation. This may be beneficial for understanding the developmental mechanisms of TNBC, and to identify potential biomarkers for the diagnosis and therapy of this disease.

Materials and methods

Cell lines and reagents. The MDA-MB-231 and MDA-MB-468 human TNBC cell lines, and the MCF10A normal human mammary epithelial cell line were purchased from American Type Culture Collection (Manassas, VA, USA). The MCF10A cells were maintained in DMEM/Ham's F-12 (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA) supplemented with 100 ng/ml cholera toxin (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany), 20 ng/ml epidermal growth factor (Sigma-Aldrich, Merck KGaA), 0.01 mg/ml insulin (Sigma-Aldrich, Merck KGaA), 500 ng/ml hydrocortisone (Sigma-Aldrich, Merck KGaA), and 5% chelex-treated horse serum (Sigma-Aldrich, Merck KGaA). The MDA-MB-468 and MDA-MB-231 cells were cultured in RPMI-1640 medium (Gibco; Thermo Fisher Scientific, Inc.) or L-15 (Gibco; Thermo Fisher Scientific, Inc.) The culture medium was supplemented with 10% (v/v) fetal bovine serum (FBS; Gibco; Thermo Fisher Scientific, Inc.), 100 U/ml streptomycin (Gibco; Thermo Fisher Scientific, Inc.), and 5% chelex-treated horse serum (Sigma-Aldrich, Merck KGaA). The MDA-MB-468 and MDA-MB-231 cells were cultured in RPMI-1640 medium (Gibco; Thermo Fisher Scientific, Inc.) or L-15 (Gibco; Thermo Fisher Scientific, Inc.) in an incubator at 37˚C.

Tissue collection. In total, 30 patients with primary TNBC, treated at Wuhai People’s Hospital, (Wuhai, China), participated in the present study. The primary TNBC tumor tissues and adjacent normal tissues were collected, washed, and frozen in liquid nitrogen immediately following surgery. No patients had received other treatments prior to surgery. Informed consent regarding the use of these samples was obtained from each patient. The present study was approved by the Ethics Committee of Wuhai People’s Hospital. Patient information is summarized in Table I.

Cell transfection. A total of 2x10^5 cells/well were seeded in 6-well plates and incubated in an incubator at 37˚C with 5% CO_2 for 24 h to a confluence of 50-60%. The cells were transfected with control small interfering (si)RNA and HOST2 siRNA (Invitrogen; Thermo Fisher Scientific, Inc.) using Lipofectamine RNAiMAX (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer’s protocol, and incubated at room temperature for 20 min. The Inc-HOST2 siRNA sequences used were as follows: HOST2 siRNA, 5'-GACTAAACAAAGTGCTTAAATT-3' and HOST2 siRNA#, 5'-TGACTAACAAGGTCTTTAATT-3'. The negative control siRNA sequence used was 5'-TTCTCCGAACGTGTCACGTTT-3'. The transfected cells were washed with PBS three times, followed by incubation with 1.5 ml fresh serum/antibiotic-free MEM for 48 h for the subsequent experiments.

Western blot analysis. Proteins were extracted from the cell lysates using RIPA buffer (Roche Diagnostics, Shanghai, China). The protein concentration was determined using a BCA kit (Beyotime Institute of Biotechnology, Shanghai, China). A total of 10 µg protein per sample was separated by 10% polyacrylamide gel electrophoresis (PAGE). The PVDF membranes were blocked with 5% bovine serum albumin (Sigma-Aldrich, Merck KGaA) at room temperature for 1 h, and incubated with primary antibodies against CDK6 (cat. no. 13331; 1:1,000) and GAPDH (cat. no. 5174; 1:5,000) (Cell Signaling Technologies, Inc., Danvers, MA, USA) at 4˚C overnight. The following day, the PVDF membranes were washed three times with TBS-Tween, incubated with a secondary antibody (horseradish peroxidase-linked anti-rabbit IgG; Cell Signaling Technologies, Inc., cat. no. 7074, 1:10,000) at room temperature for 1 h, and washed three times again with TBST. Finally, the proteins were visualized using chemiluminescence reagent and images were captured with the Bio-Rad Gel Doc EZ system (Bio-Rad Laboratories, Inc., Hercules, CA, USA).

Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) analysis. Total RNA was extracted from the tissues or cells with TRIZol (Invitrogen; Thermo Fisher Scientific, Inc.), and cDNA was synthesized using a reverse transcription kit (Promega Corporation, Madison, WI, USA).

To evaluate the expression of let-7b, the PCR reaction contained 5 µl 2X SYBR-Green Taq reaction liquid, 0.2 µl Rox II, 0.2 µl sense primer, 0.2 µl antisense primer, 1 µl cDNA and 3.4 µl ddH_2O. The thermocycling conditions were as follows:

### Table I. Association between the expression of HOST2 and patient clinical and pathological characteristics.

<table>
<thead>
<tr>
<th>Clinical pathological feature</th>
<th>Cases (n)</th>
<th>Expression of HOST2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinicopathological Cases</td>
<td>Low (n)</td>
<td>High (n)</td>
</tr>
<tr>
<td>Age (years)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤45</td>
<td>10</td>
<td>4</td>
</tr>
<tr>
<td>&gt;45</td>
<td>20</td>
<td>11</td>
</tr>
<tr>
<td>Tumor size (cm)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤2</td>
<td>12</td>
<td>7</td>
</tr>
<tr>
<td>&gt;2</td>
<td>18</td>
<td>8</td>
</tr>
<tr>
<td>TNM stage</td>
<td></td>
<td></td>
</tr>
<tr>
<td>I</td>
<td>8</td>
<td>7</td>
</tr>
<tr>
<td>II</td>
<td>10</td>
<td>5</td>
</tr>
<tr>
<td>III</td>
<td>12</td>
<td>3</td>
</tr>
<tr>
<td>Ki-67</td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤20</td>
<td>17</td>
<td>11</td>
</tr>
<tr>
<td>&gt;20</td>
<td>13</td>
<td>4</td>
</tr>
</tbody>
</table>

*P<0.05 was considered to indicate a statistically significant difference. HOST2, human ovarian cancer-specific transcript 2; TNM, tumor-node-metastasis.
and digested into a single-cell suspension using 0.25% trypsin. When the transfected cells reached 60% confluence, they were washed by PBS three times and re-suspended and adjusted to a density of 1x10⁶ cells/ml. The cells were then seeded in a 96-well plate (200 µl/well) at a density of 6x10³ cells/well, and cultured for 48 h at 37°C. Following this, 10 µl CCK-8 solution was added to each well, and the cells were cultured for another 2 h at 37°C. The optical density (OD) in each well was evaluated at a wavelength of 450 nm.

Flow cytometry with PI staining. At 48 h post-transfection, the cells were washed three times with ice-cold PBS and centrifuged at 4°C for 10 mins (1,000 x g). The cells were re-suspended and adjusted to a density of 1x10⁶ cells/ml. The cells were fixed with 1 ml ice-cold 75% ethanol overnight at 4°C. The following day, the cells were washed three times with PBS, followed by aspiration of the supernatant. The cells were then treated with 100 µl RNaseA in a water bath at 37°C for 30 min, followed by staining with 400 µl PI and 1 µl 10X ROX and 1.4 µl water without RNase. The thermocycling conditions were as follows: 95°C for 15 min, followed by 95°C for 10 sec, annealing for 30 sec and extension for 30 sec (40 cycles). The primers were designed using Primer 5.0 software, according to the gene sequences in the Genebank database (www.ncbi.nlm.nih.gov/). The sequences were as follows: HOST2 forward, 5'-CCACCAGAGGAAAGGTTGAGTGA-3' and reverse, 5'-AAGCCGTCTCAGAATTTGCGT-3'; CDK6 forward, 5'-TGGAAGGCGCGTCCGACGACC-3' and reverse, 5'-CTCCAGCGGTCCAAGGTC-3'; GAPDH forward, 5'-GTTGGAAGGGTGGATGACCT-3' and reverse, 5'-GGGTGCTTCGAGGTCAACG-3'; U6 forward, 5'-CTCGTCGTGGGCTAGCT-3' and reverse, 5'-AATGCTTGGTATCTTCTGGACTT-3'. The U6 was used as an internal control.

Cell Counting kit-8 (CCK-8) assay. When the transfected cells reached 60% confluence, they were washed by PBS three times and digested into a single-cell suspension using 0.25% trypsin. The cells were then seeded in a 96-well plate (200 µl/well) at a density of 6x10³ cells/well, and cultured for 48 h at 37°C. Following this, 10 µl CCK-8 solution was added to each well, and the cells were cultured for another 2 h at 37°C. The optical density (OD) in each well was evaluated at a wavelength of 450 nm.

Overexpression of let-7b. miRNA (miR)-NC mimics and let-7b mimics were synthesized by Guangzhou Ribobio Co., Ltd. (Guangzhou, China). To induce let-7b overexpression, the let-7b mimics were mixed with Lipofectamine 2000 (Invitrogen; Thermo Fisher Scientific, Inc.) in serum-free medium for 15 mins, and then added to the cells.

Bioinformatics analysis and dual luciferase activity assay. The bioinformatics analysis of the potential binding site between let-7b and CDK6 3'UTR was performed on miRDB (http://mirdb.org/). Oligonucleotides containing the CDK6 cDNA fragment, including let-7b binding sites, were amplified from the MDA-MB-231 cells and cloned into pmirGLO plasmids (Promega Corporation). Mutant CDK6 (pmirGLO-CDK6-MUT) served as a negative control and was generated by site-directed mutagenesis PCR using platinum pfx DNA polymerase, according to the manufacturer's protocol. The luciferase reporter plasmid and let-7b mimics or miR-NC mimics were co-transfected into MDA-MB-231 cells using Lipofectamine 2000. At 48 h post-transfection, the relative luciferase activity was examined using a Dual-Luciferase Reporter Assay system (Promega Corporation) in a luminometer. For the analysis of let-7b and miR-NC mimics, the MCF-10A immortal epithelial breast cell line, expression of HOST2 was higher in MDA-MB-231 and MDA-MB-468 TNBC cell lines. "P<0.0001. TNBC, triple negative breast cancer; HOST, human ovarian cancer-specific transcript 2.
Statistical analysis. SPSS 21.0 (IBM SPSS, Armonk, NY, USA) was used for statistical analysis. The data are presented as the mean ± standard deviation. Comparisons of two groups were made using Student's t-test. One-way analysis of variance followed by Newman-Keuls post hoc analysis was used to compare the means of multiple groups. The association between HOST2 levels and patient clinical and pathological characteristics were analysed using Chi-square test. P<0.05 was considered to indicate a statistically significant difference. The experiments were repeated three times.

Results

Overexpression of HOST2 in TNBC tumor tissues and cell lines. To evaluate the role of HOST2 in TNBC, RT-qPCR analysis was performed to compare the expression of HOST2 between TNBC tumor tissues and adjacent normal tissues. Compared with the adjacent normal tissues, the expression of HOST2 was significantly increased in the TNBC tumor tissues (Fig. 1A). The expression of HOST2 was also detected in MCF10A normal breast epithelial cells and in the MDA-MB-231 and MDA-MB-468 TNBC cell lines. Increased expression of HOST2 was observed in the TNBC cells, compared with the MCF10A cells (Fig. 1B). The potential clinicopathological implications of the expression of HOST2 were also investigated in 30 patients with TNBC. The patients were divided into low and high HOST2 expression groups. Analysis of the association between the expression of HOST2 and patient clinicopathological parameters revealed that a high expression of HOST2 was closely associated with TNBC tumor-node-metastasis stage. However, the expression of HOST2 was not associated with age, tumor size or the expression of Ki-67 (Table I).

Overall, the above results suggested the oncogenic potential of HOST2, and that it is involved in the progression of TNBC.
Silencing of HOST2 inhibits cell proliferation and cell cycle arrest in TNBC cells. The silencing of HOST2 was induced to assess the function of HOST2 in TNBC cells. HOST2 siRNA transfection decreased the expression of HOST2 in the MDA-MB-231 and MDA-MB-468 cells (Fig. 2A). The CCK-8 assay indicated that HOST2 silencing led to a significant decrease in the proliferative rate of the MDA-MB-231 and MDA-MB-468 cells (Fig. 2B and C). Cell cycle arrest was a major reason for cell proliferation inhibition. Using flow cytometric analysis, it was found that HOST2 silencing increased the proportion of MDA-MB-231 and MDA-MB-468 cells in the G1 phase (Fig. 2D-G), but did not affect the apoptotic cell rate of the MDA-MB-231 and MDA-MB-468 cells (data not shown). Therefore, HOST2 may promote TNBC progression through regulation of the G1-S checkpoint.

Silencing of HOST2 represses the expression of CDK6 in TNBC cells. The cyclin D-CDK4/6 complex has been demonstrated to be pivotal in controlling the G1-S checkpoint (15). The analysis of gene expression levels in TNBC tumor tissues revealed that the expression of CDK6 was positively correlated with that of HOST2, whereas the expression of CDK4 was not (Fig. 3A and B). Consistently, silencing of the expression of HOST2 decreased the expression of CDK6 in the MDA-MB-231 and MDA-MB-468 cells (Fig. 3C). During the G1-S phase, the phosphorylation of RB1 by CDK6 permits the transcription of S phase genes, and is required for DNA replication (16). Western blot analysis revealed that the protein expression level of CDK6 and the phosphorylation of RB1 were reduced following HOST2 silencing in the MDA-MB-231 and MDA-MB-468 cells (Fig. 3D). To determine whether CDK6 regulated HOST2, CDK6 siRNA was transfected into TNBC cells. The trans-
Infection of CDK6 siRNA decreased the expression of CDK6 (Fig. 3E). CDK6 silencing did not alter the level of HOST2 in the MDA-MB-231 or MDA-MB-468 cells (Fig. 3F). Collectively, the above data suggested that CDK6, a key regulatory kinase in the cell cycle, was negatively regulated by HOST2 in TNBC cells.
HOST2 regulates CDK6 via the repression of let-7b. IncRNAs can function as sponge RNAs to regulate gene expression (17). A previous study revealed that HOST2 repressed the expression of let-7b in breast cancer (18). To determine whether HOST2 controlled CDK6 levels through the sponging of let-7b, the expression of HOST2 was silenced in the TNBC cells. The knockdown of HOST2 increased the expression levels of let-7b in the MDA-MB-231 and MDA-MB-468 cells (Fig. 4A). To further validate the regulation of let-7b by HOST2, another independent HOST2 siRNA (HOST2 siRNA#) was used to knock down HOST2 in the TNBC cells. Consistent with the HOST siRNA, transfection with HOST2 siRNA# also increased the expression of let-7b (Fig. 4B and C). In addition, the transfection of let-7b mimics reduced the luciferase activity of MDA-MB-231 cells transfected with pGL3-HOST2 WT containing a putative binding site for let-7b (Fig. 4D). Similarly, in the MDA-MB-468 cells, the overexpression of let-7b repressed luciferase activity in the cells transfected with pGL3‑HOST2 WT (Fig. 4E), indicating that HOST2 directly repressed the expression of let-7b. In addition, the enhanced expression of let-7b caused by transfection of let-7b mimics (Fig. 4F) reduced the expression of CDK6 at the mRNA and protein levels in the MDA‑MB‑231 and MDA‑MB‑468 cells (Fig. 4G and H). These findings suggested that HOST2 controlled the expression of CDK6 through sponging of let-7b in the TNBC cells.

Let-7b directly binds to the 3'UTR of CDK6 mRNA. Whether let-7b directly regulated the level of CDK6 was investigated. The prediction of let-7b binding sites indicated that let-7b may directly bind to the 3'UTR of CDK6 mRNA (Fig. 5A). A dual luciferase assay was used, which demonstrated that the overexpression of let-7b caused the reduced luciferase activity of cells transfected with CDK6 3'UTR-WT, but not 3'UTR-Mut (Fig. 5B). These results confirmed that let-7b targeted the 3'UTR of CDK6 mRNA.

Expression of let-7b is negatively associated with expression levels of HOST2 and CDK6 in TNBC tumor tissues. To further evaluate the clinical significance of HOST2/let7b/CDK6 in TNBC, RT-qPCR analysis was performed to detect the expression of let-7b, and Pearson's correlation analysis was used to analyze the results. Compared with matched normal tissues, decreased expression of let-7b was observed in TNBC tumor tissues (Fig. 6A). Additionally, a significant negative correlation was identified between the expression of let-7b and HOST2, and the expression of let-7b and CDK6 in TNBC tumor tissues (Fig. 6B and C).

Discussion
TNBC is characterized by an aggressive phenotype and a high rate of relapse (19). In the absence of well-defined molecular targets, chemotherapy is the first line of treatment for TNBC, but this often results in chemoresistance, and the mortality rate remains high (20). Several reports have indicated that IncRNAs are important regulators of TNBC progression (21-23). In the present study, IncRNA-HOST2 was identified as an oncogene in TNBC, and may provide a novel therapeutic target for TNBC.

HOST2 was first defined in human ovarian cancer and functions as an oncogene through binding to let-7b (24,25). HOST2 has been demonstrated to regulate cell proliferation, migration, invasion and cell apoptosis in human osteosarcoma and hepatocellular carcinoma cells (12,26). A previous study showed that HOST2 was overexpressed in breast cancer and that the silencing of HOST2 inhibited the migration and invasion of MCF7 cells, a luminal breast cancer cell line (18). Through comparison of the expression of HOST in TNBC tumor tissues and matched normal tissues, a marked increase in HOST2 was revealed in TNBC tumor tissues. In addition, the expression of HOST2 was significantly increased in TNBC cell lines compared with normal breast epithelial cells. The silencing of HOST2 decreased the rate of cell proliferation of the two TNBC cell lines. Flow cytometric analysis indicated that HOST2 silencing led to an enrichment of cells in the G0/G1 phase, but did not significantly elevate apoptotic cell rate, suggesting that HOST2 may promote TNBC proliferation via accelerating the cell cycle.

The above results of the cell cycle assay showed that HOST2 regulated the G0/G1 phase in cells. Through a literature review, it was noted that CDK6 is a major G0/G1 checkpoint regulator and frequently deregulated in cancer cells (27); the expression of CDK6 has been associated with poor survival outcomes and is considered to be a promising therapeutic target for TNBC.

Figure 5. CDK6 is a direct target of let-7b. (A) Sequence alignment of let-7b to the 3'UTR of CDK6 mRNA. (B) Transfection of let-7b mimics decreased the relative luciferase activity of cells transfected with CDK6 3'UTR-WT, but not 3'UTR-Mut. ***P<0.0001. CDK6, cyclin-dependent kinase 6; 3'UTR, 3' untranslated region; WT, wild-type; Mut, mutant; miR, microRNA; NC, negative control.
target for TNBC (28). The results suggested that CDK6 was a key regulator in the G\textsubscript{1}/S phase and is pivotal in the progression of TNBC. Other lncRNAs, including gadd7, GAS5 and MYU, have been reported to regulate the expression of CDK6 in different cellular contexts (29-31). In the present study, following the silencing of HOST2, the expression of G\textsubscript{1}/S cell cycle regulator CDK6, was detected. It was found that CDK6 was downregulated following HOST silencing, and a positive correlation between the expression of HOST2 and CDK6 was identified in the TNBC tumour tissues. In addition, the silencing of HOST2 decreased the expression of CDK6 in TNBC cell lines, indicating that HOST2 may enhance the expression of CDK6. The regulatory association between HOST2 and CDK6 may explain the cell cycle redistribution following HOST2 knockdown. A previous study showed that several lncRNAs function as potent miRNA sponges to regulate gene expression (32). It has been suggested that abundant lncRNAs can sequester miRNAs away from their targeted mRNAs (33). A previous study showed that let-7b was a target of HOST2 (25). The present study further confirmed that HOST2 sponged let-7b to downregulate its expression in MDA-MB-231 and MDA-MB-468. In addition, bioinformatics analysis indicated complementary sequences between let-7b and the 3'UTR of CDK6 mRNA. A dual luciferase assay confirmed let-7b as a direct regulator of CDK6, and the results of western blot and RT-qPCR analyses confirmed that let-7b suppressed the expression of CDK6. Of note, the expression of let-7b was downregulated in TNBC tumour tissues, and its expression was negatively correlated with that of CDK6 and HOST2.

In conclusion, the present study suggested that an HOST2/let-7b/CDK6 expression axis is involved in the promotion of TNBC proliferation. Mechanistically, downregulation of the expression of HOST2 resulted in increased expression of let-7b, a tumor suppressor, and decreased expression of CDK6, resulting in the alteration of cell cycle distribution. Therefore, HOST2 may be a candidate therapeutic target for the treatment of patients with TNBC in the near future.

Acknowledgements
Not applicable.

Funding
No funding was received.

Availability of data and materials
Details of data and materials are available from the correspondence author on request.

Authors' contributions
YucZ was responsible for study design. YueZ, HZ and YuZ performed most of experiments. HK, WH helped with collection

Figure 6. Expression of let-7b is inversely correlated with HOST2 and CDK6 in tumor tissues from patients with TNBC. (A) Compared with matched normal tissues, let-7b levels were lower in tumor tissues from patients with TNBC. (B) Pearson's analysis of let-7b levels with HOST2 levels showed an inverse correlation. (C) Pearson's analysis of let-7b levels with CDK6 levels showed a negative correlation. ***P<0.0001. TNBC, triple negative breast cancer; HOST, human ovarian cancer-specific transcript 2; CDK, cyclin-dependent kinase.
references